Treatment and survival for patients with localized primary ocular adnexal extranodal marginal zone lymphoma
- 19 March 2024
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 38 (4) , 914-917
Abstract
No abstract availableKeywords
All Related Versions
This publication has 14 references indexed in Scilit:
- Influence of age on long-term net survival benefit for early-stage MALT lymphomas treated with radiotherapy: A SEER database analysis (2000–2015)Radiotherapy and Oncology, 2022
- Long‐term outcomes of patients with conjunctival extranodal marginal zone lymphomaAmerican Journal of Hematology, 2022
- 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trialThe Lancet Oncology, 2021
- Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2020
- Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosisInternational Journal of Clinical Oncology, 2019
- Long-term outcome, relapse patterns, and toxicity after radiotherapy for orbital mucosa-associated lymphoid tissue lymphoma: implications for radiotherapy optimizationJapanese Journal of Clinical Oncology, 2019
- Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphomaAnnals of Oncology, 2017
- Radiation Therapy Administration and Survival in Stage I/II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid TissueInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Survival of patients with marginal zone lymphomaCancer, 2012
- Rapidly Increasing Incidence of Ocular Non-Hodgkin LymphomaJNCI: Journal of the National Cancer Institute, 2006